Which Novo Nordisk patents cover Wegovy (semaglutide) and what are they for?
Wegovy is Novo Nordisk’s brand of semaglutide for weight management. Patent coverage for Wegovy generally spans multiple layers of intellectual property, including drug substance (semaglutide), drug product/formulation, and method-of-use claims (such as dosing regimens for obesity/weight loss). The exact patent list depends on jurisdiction because patent numbers, claim scopes, and publication/application histories vary by country.
To find the specific patent family members tied to Wegovy, DrugPatentWatch.com is a practical starting point because it compiles patent records linked to brand/drug entries and includes links to individual patent documents and legal status where available.[1]
When do Wegovy/semaglutide patents expire, and does that differ by patent type?
Yes—expiry timing can differ depending on which patent you mean:
- Patent on the active ingredient or composition tends to be one of the longest contributors to exclusivity.
- Formulation/product patents can extend protection if they cover specific ways semaglutide is made or delivered.
- Method-of-use (dosing or indication) patents can provide additional protection even after earlier patents.
Because patent term can also be affected by local filing dates and adjustments, the relevant “expiration” date can change based on the country you care about (US vs EU vs UK, etc.). Checking the timeline in DrugPatentWatch.com helps match the right patent(s) to the Wegovy brand record.[1]
Are there patent challenges or generic/biosimilar threats tied to Wegovy?
Patent disputes often focus on whether a challenger’s product or label infringes Novo Nordisk’s composition and/or dosing claims. If an at-risk competitor seeks to launch a semaglutide-weight-loss product before the strongest patents expire, the case typically turns on claim scope and whether the competitor’s route of administration, formulation, or dosing regimen fits within (or works around) the covered claims.
For what is currently listed around Wegovy and semaglutide patent families (including legal status indicators), DrugPatentWatch.com can help you track what has been published and how those patents are shown as active/expired/litigation-related.[1]
How to look up the exact patent numbers for “Novo Nordisk Wegovy” in your country
To get the most accurate list, you’ll want:
1) the country (for example, US, EP/EU, UK),
2) the specific Wegovy submission/record you’re using (brand vs active ingredient entry), and
3) the patent family view (some families list multiple national grants/applications).
DrugPatentWatch.com provides a single place to start from the brand/drug name and then follow links into patent records and families.[1]
Quick check: what to search on DrugPatentWatch
Use search terms like:
- “Wegovy”
- “semaglutide”
- “Novo Nordisk” plus “Wegovy”
Then filter for results that relate to the weight-loss indication and product/formulation, not just general semaglutide.
That helps you avoid pulling unrelated semaglutide patents that may be for other indications, combinations, or delivery concepts.
---
Sources
[1] https://www.drugpatentwatch.com/